Here is another pre-ASH press release from PRNewswire.com:
ENMD-2076 Phase 1 Data in Hematological Studies to be Presented at ASH
ENMD-2076 Multiple Myeloma and Leukemia Abstracts to be Published in Blood
ROCKVILLE, Md., Nov. 9, 2010 /PRNewswire-FirstCall:
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced presentations for its Phase 2 oncology drug candidate, ENMD-2076. Data for the ENMD-2076 Phase 1 studies in multiple myeloma and leukemia will be presented by EntreMed investigators at the 2010 Annual Meeting of the American Society of Hematology (ASH) to be held December 4-7 at the Orange County Convention Center in Orlando, Florida. Both abstracts were accepted for poster presentation at the meeting and will be published in the print and online November 19, 2010 supplemental volume of Blood.
The Phase 1 data will be presented as listed below.
•Poster Session: Myeloma – Therapy, excluding transplantation: Poster I; Saturday, December 4, 2010 – 9:00 a.m. – 7:30 p.m. (author presentation time 5:30 – 7:30 p.m.); Hall A3/A4, Board No. I-937; Title: “Clinical activity of a novel multiple tyrosine kinase and Aurora kinase inhibitor, ENMD-2076, against multiple myeloma: interim Phase 1 trial results.”
•Poster Session: Acute myeloid leukemia – Therapy, excluding transplantation: Poster III; Monday, December 6, 2010 – 10:00 a.m. – 8:00 p.m. (author presentation time 6:00 – 8:00 p.m.); Hall A3/A4, Board No. III-86; Title: “A Phase 1 study of ENMD-2076 in patients with relapsed or refractory leukemia.”
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrated significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. While ENMD-2076 is currently in a Phase 2 trial in ovarian cancer, preclinical and clinical activities are ongoing in assessing the compound’s applicability in other forms of cancer.
EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia. Additional information about EntreMed is available on the Company’s web site at www.entremed.com and in various filings with the Securities and Exchange Commission.
I don’t usually include the “about” sections, but in this case I thought it was appropriate, since EntreMed, Inc. is not a very well known company. I first wrote about ENMD-2076 last July: New British Anti-Myeloma Drug Study Shows Promise.
Note ENMD-2076 is an oral medication which may work against several different types of cancer. That in itself isn’t all that unusual. But the fact it is being tested in blood cancer and a solid tumor application is unusual–especially if ENMD-2076 works against all three cancer types.
You will be reading about more and more experimental blood cancer therapies as ASH draws closer.
Feel good and keep smiling! Pat